Long-term Androgen Deprivation Therapy Combined with High-dose Radiation Therapy for Prostate Cancer Improves Survival

Long-term Androgen Deprivation Therapy Combined with High-dose Radiation Therapy for Prostate Cancer Improves Survival
japanese PAH studyA new study entitled "Randomized Phase III Trial of Adjuvant Androgen Deprivation in Combination with High-dose Conformal Radiotherapy in Intermediate and High-Risk Localized Prostate Cancer," presented at this years' American Society for Radiation Oncology's (ASTRO's) 56th Annual Meeting shows the positive outcomes in the survival rates of treating prostate cancer patients with a combination of high-dose radiation therapy (HDRT) with androgen hormone suppression therapy (ADT). The meeting is being held at the Moscone Center in San Francisco, September 14-17, 2014. The study followed 362 patients with prostate cancer from 9 cancer centers in Spain. Prostate cancer cells use androgen hormones (like testosterone) to grow. Thus, a current treatment for locally advanced prostate cancer relies on a co-treatment of radiation therapy (RT) with ADT. In this study, the team of scientists evaluated if a treatment of HDRT combined with 28 months of androgen deprivation (a long-term androgen deprivatio
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *